Shares in the nanocap biotech shot up more than 100% in premarket trading before falling away somewhat as people dug deeper into the data.

In this week's EuroBiotech Report, EMA raises staff retention forecast, Berman swaps AstraZeneca for Immunocore and Juvenescence raises $46 million.

Gilead’s VP of clinical research, Erin Quirk, is joining the NASH and cancer-focused Terns Pharmaceuticals as its new chief medical officer.

The failure wiped two-thirds off the value of Aptinyx, which went public last year with a $118 million IPO.

Immuno-oncology player Five Prime is axing 20% of its workforce and its early-stage R&D in order to focus on its clinical cancer programs.

The series B round will support the startup’s efforts to build a portfolio of subsidiaries with assets targeting eight aging pathways.

The investment, which values Juvenescence at $400 million, tees the anti-aging startup to advance its multiasset pipeline.

The FDA plans to hire at least 50 reviewers for cell and gene therapies ahead of what it describes as a surge of products entering development.